Zynex, Inc. Stock Plummets to New 52-Week Low of $1.22

Zynex, Inc., a microcap company in the Pharmaceuticals & Biotechnology sector, has reached a new 52-week low of USD 1.22 on October 30, 2025. This significant decline reflects a challenging year for the company, which has seen its stock price plummet by 86.8% over the past year, contrasting sharply with the S&P 500's performance of 18.13% during the same period.
The company's financial metrics indicate ongoing difficulties, with a pre-tax profit of USD -11.12 million, marking a staggering decline of 336.56%. Additionally, Zynex's operating cash flow has reached its lowest point at USD -7.19 million, further highlighting the financial strain the company is under. The debt-to-equity ratio stands at 36.51, and the return on equity is notably negative at -2,272.96%.

With a market capitalization of USD 46 million, Zynex's stock has consistently underperformed against the benchmark, generating negative returns over the last three years. The stock's 52-week high was recorded at USD 9.33, underscoring the extent of its recent decline.